SCHEMBL4239727

SCHEMBL4239727

Cc1ccccc1Nc1cc(Nc2cccc(C(N)=O)c2)ncn1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNNI3K Q59H18 1/20 0.60
ABL1 P00519 1/20 0.57
BCR P11274 1/20 0.57
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
YES1 P07947 1/20 0.53
LYN P07948 1/20 0.53
FGR P09769 1/20 0.53
EPHA1 P21709 1/20 0.53
EPHA2 P29317 1/20 0.53
EPHA3 P29320 1/20 0.53
EPHB2 P29323 1/20 0.53
CSK P41240 1/20 0.53
TXK P42681 1/20 0.53
SYK P43405 1/20 0.53
BLK P51451 1/20 0.53
BMX P51813 1/20 0.53
EPHB3 P54753 1/20 0.53
EPHA5 P54756 1/20 0.53
EPHA4 P54764 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4239718 0.85 ABL1 (0.57) ABL1BCRROCK1
SCHEMBL31060173 0.81 LCK (0.79) LCKFYNYES1LYNFGR
SCHEMBL4239735 0.81 TNNI3K (0.62) TNNI3KBLKS1PR1LMNAMAPT
SCHEMBL13777939 0.77 TUBB4A (0.68) TNNI3KLCKSYKBMXS1PR1
SCHEMBL4239038 0.77 AURKA (0.70) ABL1BCRSYKROCK1MAPT
SCHEMBL2225936 0.76 TNNI3K (0.77) TNNI3K
SCHEMBL27607062 0.74 ROCK1 (0.65) ABL1BCRROCK1
SCHEMBL4098723 0.74 CDK9 (0.67) LMNAMAPT
SCHEMBL22458668 0.73 ABL1 (0.70) ABL1BCRROCK1LMNATP53
SCHEMBL30400745 0.72 NNMT (0.58) SYKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181991-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC 2009-07-16 US claimed
EP-1943233-A2 COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS IRM, LLC (BM) 2008-07-16 EP claimed
WO-2007056151-A2 PROTEIN KINASE INHBITORS IRM LLC (BM) 2007-05-18 WO claimed
US-20090181991-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC 2009-07-16 US disclosed
EP-1943233-A2 COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS IRM, LLC (BM) 2008-07-16 EP disclosed
WO-2007056151-A2 PROTEIN KINASE INHBITORS IRM LLC (BM) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181991-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ERBB2, BMX, ERBB3 TNNI3K 477/4885ABL1 75/4885BCR 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.